Table 3.

Outcomes.

	KT following SOT (n = 97)	Control (n = 154)	p-value
CMV DNAemia incidence, n (%)	38 (39.2)	75 (48.7)	0.14
Time to CMV DNAemia post-KT (months), median (IQR)	1.6 (0.7–5.8)	2.6 (1.5–8.1)	0.04
Serum creatinine (mg/dl) at 1 year, median (IQR)	1.4 (1.1–1.7)	1.4 (1.1–1.7)	0.70
GFR at 1 year, median (IQR)	54 (43–64)	52 (43–63.8)	0.83
BPAR, n (%)
TCMR (grade 1a or higher)	3 (3.1)	8 (5.2)	0.43
ABMR	2 (2.1)	1 (0.6)	—

TCMR, T-cell-mediated rejection; ABMR, antibody-mediated rejection.